This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Arch Intern Med. 2002;162:481-482.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Interferon has been used as the standard therapy for chronic hepatitis C. However, interferon use has various adverse effects, including depression, hematological abnormalities, and autoimmune diseases. Autoimmune diseases are induced by either the exacerbation of preexisting disorders or de novo induction.^1-2 These effects are attributed to the immunomodulatory effects of interferon. We describe a rare patient who developed capillary leak syndrome with monoclonal gammopathy after successful treatment with interferon alfa for her chronic hepatitis C.

Report of a Case

A 49-year-old woman was treated with interferon alfa for chronic hepatitis C, starting in April 1989. Before the treatment, serum aspartate aminotransferase and alanine aminotransferase levels were 167 U/L and 184 U/L, respectively. Testing for hepatitis C virus RNA was positive in serum and the genotype was 2a. Serum IgG level was 3614 mg/dL without a monoclonal gammopathy. Antinuclear antibody testing was positive, with a titer of 80. The patient's thyroid function was normal, although . . . [Full Text of this Article]

Comment


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?